Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
about
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@ast
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@en
type
label
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@ast
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@en
prefLabel
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@ast
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@en
P2093
P2860
P356
P1476
Safety and Immunogenicity of a ...... scalation Phase I Study Trial.
@en
P2093
Amparo Macías
Anabel Lavastida
Angel Casacó
Barbara Wilkinson
Belinda Sánchez
Eduardo Suarez
Iraida Caballero
Javier Rivero
Joaquín González
Kelly Coba
P2860
P356
10.3389/FPHAR.2017.00263
P577
2017-05-10T00:00:00Z